Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 25, Issue 23, pp. 7202-7217
PubMed
Published By
Print ISSN
Online ISSN
History
- Received August 27, 2018
- Revision received March 18, 2019
- Accepted September 6, 2019
- Published first September 12, 2019.
Article Versions
- Previous version (September 12, 2019 - 06:24).
- Previous version (October 22, 2019 - 07:14).
- You are viewing the most recent version of this article.
Copyright & Usage
©2019 American Association for Cancer Research.
Author Information
- Victoria E. Wang1,2,
- Jenny Y. Xue3,4,5,
- Dennie T. Frederick6,
- Yi Cao7,
- Eva Lin7,
- Catherine Wilson7,
- Anatoly Urisman2,8,
- David P. Carbone9,
- Keith T. Flaherty6,
- Rene Bernards10,
- Piro Lito3,4,5,
- Jeff Settleman7,*, and
- Frank McCormick2,*
- 1Department of Medicine, University of California, San Francisco, San Francisco, California.
- 2Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
- 3Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
- 4Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, New York.
- 5Weill Cornell Medical College, Cornell University, New York, New York.
- 6Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
- 7Discovery Oncology, Genentech, South San Francisco, California.
- 8Department of Pathology, University of California, San Francisco, San Francisco, California.
- 9The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
- 10Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- ↵*Corresponding Authors:
Frank McCormick, UCSF Helen Diller Comprehensive Cancer Center, 1450 Third Street, San Francisco, CA 94158. Phone: 415-502-1710; Fax: 415-502-1712; E-mail: Frank.mccormick{at}ucsf.edu; and Jeff Settleman, Pfizer, Inc., Science Center Drive, San Diego, CA 92121. E-mail: jeffrey.settleman{at}pfizer.com
December 2019
Volume 25, Issue 23
Volume 25, Issue 23
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
Jump to section
Advertisement